Related Experiment Videos
[Autologous bone marrow transplantation in malignant hematologic diseases]
H E Johnsen1, H Birgens, N E Hansen
1Københavns Amts Sygehus i Gentofte, medicinsk-haematologisk afdeling C.
Ugeskrift for Laeger
|June 17, 1991
Summary
Autologous bone marrow transplantation (Auto-KMT) is a viable treatment for relapsed lymphoma and acute myeloblastic leukemia. While challenges like graft-versus-leukemia effects exist, mortality is acceptable, suggesting future use in earlier disease stages.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Context:
- Autologous bone marrow transplantation (Auto-KMT) uses a patient's own marrow after high-dose chemotherapy for cancer treatment.
- It avoids graft-versus-host disease and donor limitations associated with allogeneic transplants.
- Challenges include cytotoxic therapy efficacy and the absence of a graft-versus-leukemia effect.
Purpose:
- To review current literature and define the role of Auto-KMT in treating malignancies.
- To identify patient subsets who may benefit from Auto-KMT.
- To assess the safety and efficacy of Auto-KMT.
Summary:
- Auto-KMT is indicated for relapsed lymphoma and acute myeloblastic leukemia in second remission.
- Associated mortality is deemed acceptable.
- The study suggests potential future applications in earlier disease stages.
Impact:
- Auto-KMT offers an alternative to allogeneic transplantation with reduced risks of graft-versus-host disease.
- Current indications are specific, but future use may expand to earlier stages of leukemia and lymphoma.
- Further research and clinical trials are needed to fully define its role and optimize outcomes.